Literature DB >> 6563943

Immunologic enhancement of experimental metastasis in the rat.

J R Starkey, S S Ristow, T L McDonald, J E Talmadge.   

Abstract

Using a series of immunologically cross-reactive metastatic tumor variants, we demonstrate that serum from animals bearing pulmonary tumor colonies possesses enhancing properties in the experimental metastasis (lung colony) assay. Enhancement is produced by chronic serum administration and promotes the growth of tumor cells arrested in the lungs which would not otherwise proliferate to form grossly detectable lung nodules. Tumor-bearer serum from animals with lung colonies derived from the most highly metastatic variant examined is shown to possess enhancing properties in both BD-IX(H-1d) and BD-IV(H-1d) rat strains, while tumor-bearer serum from animals with lung colonies derived from the less metastatic parent tumor cell line possesses enhancing properties in the BD-IX rat strain only. Removal of immunoglobulin from enhancing serum by affinity column chromatography simultaneously removes the enhancing factor(s), and enhancing activity correlates with the presence of increased levels of Clq-binding immune complexes in the serum. Serum levels of immune complexes are shown to be more elevated in serum from animals bearing lung colonies derived from the most highly metastatic variant. The enhancing moieties are shown to bind to concanavalin A, but not to staphylococcal protein A, and the active fraction elutes from concanavalin A-Sepharose with alpha-methyl-mannoside. Consideration of immunoprecipitation studies on whole and fractionated enhancing sera, along with studies on affinity purified isotype fractions reveals that the activity resides with antibodies of IgG2b subclass.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6563943     DOI: 10.1007/bf00205496

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  53 in total

1.  Passive enhancement of mouse tumor allografts by alloantibodies is Fc-dependent.

Authors:  R M de Waal; I M Cornelissen; P J Capel; R A Koene
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

2.  Alteration of in vitro anti-tumor activity of tumor-bearer sera by absorption with Staphylococcus aureus, Cowan I.

Authors:  G Steele; J Ankerst; H O Sjögren
Journal:  Int J Cancer       Date:  1974-07-15       Impact factor: 7.396

3.  Antibody-mediated suppression of tumor growth. II. Macrophage and platelet cooperation with murine IgG1 isolated from alloantiserum.

Authors:  R J Johnson; G R Pasternack; H S Shin
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

4.  Correlation between immune complexes and prognostic factors in Hodgkin's disease.

Authors:  P L Amlot; B Pussell; J M Slaney; B D Williams
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

5.  The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer.

Authors:  R D Rossen; M A Reisberg; E M Hersh; J U Gutterman
Journal:  J Natl Cancer Inst       Date:  1977-05       Impact factor: 13.506

6.  Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells.

Authors:  Z Steplewski; M D Lubeck; H Koprowski
Journal:  Science       Date:  1983-08-26       Impact factor: 47.728

7.  Augmentation of metastasis formation by thioglycollate-elicited macrophages.

Authors:  E Gorelik; R H Wiltrout; M J Brunda; H T Holden; R B Herberman
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

8.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

9.  Circulating immune complexes in patients with bone tumours.

Authors:  A S Eiras; R A Robins; R W Baldwin; V S Byers
Journal:  Int J Cancer       Date:  1980-06-15       Impact factor: 7.396

10.  Circulating immune complexes in sera of dogs with benign and malignant breast disease.

Authors:  B R Gordon; S Moroff; A I Hurvitz; R E Matus; E G MacEwen; R A Good; N K Day
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

View more
  1 in total

1.  Anti-tumor immunoglobulin M increases lung metastasis in an experimental model of malignant melanoma.

Authors:  Nu-man Tsai; Bing-Mae Chen; Shao-Lun Wei; Cheng-Wen Wu; Steve R Roffler
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.